XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1
FAIR VALUE MEASUREMENTS
 6 Months Ended
Jun. 30, 2024
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:
Level 1—quoted prices in active markets for identical assets and liabilities.
Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.  Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.
Level 3—unobservable inputs.
All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information.
The fair value of the Company’s long-term debt, which it considers a Level 2 measurement, is estimated using discounted cash flow analyses, based on the Company’s current estimated incremental borrowing rates for similar borrowing arrangements. The fair value of the Company’s long-term debt is estimated to be $39.8 million at June 30, 2024.
The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:
(in millions)Level 1Level 2Level 3Total
June 30, 2024
Money market funds (a)$6.4 $— $— $6.4 
Corporate bonds and notes1.4 2.9 — 4.3 
Municipal bonds— 0.6 — 0.6 
Contingent consideration— — — — 
Total$7.8 $3.5 $— $11.3 
(a)Money market funds are primarily comprised of exchange traded funds and accrued interest.
(in millions)Level 1Level 2Level 3Total
December 31, 2023
Money market funds (a)$2.2 $— $— $2.2 
Corporate bonds and notes— 8.3 — 8.3 
Municipal bonds— 0.5 — 0.5 
Contingent consideration— — (5.4)(5.4)
Total$2.2 $8.8 $(5.4)$5.6 
(a)Money market funds are primarily comprised of exchange traded funds and accrued interest.
During the six months ended June 30, 2024, the Company signed a definitive agreement to sell its EndoPredict business to Eurobio Scientific and classified the associated assets and liabilities as held for sale. The Company recognized a $10.2 million impairment based on the estimated net sale price of the EndoPredict business. The fair value used in the analysis was considered a Level 2 measurement.
The following table reconciles the change in the fair value of the contingent consideration during the periods presented:
(in millions)Carrying
Amount
Balance at December 31, 2023$5.4 
Change in fair value recognized in the Statements of Operations0.5 
Payment of contingent consideration
(5.8)
Translation adjustments recognized in Other comprehensive loss(0.1)
Ending balance at June 30, 2024$— 
For the Level 2 contingent consideration related to the acquisition of Gateway Genomics, LLC ("Gateway"), the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using then current financial projections. As of June 30, 2024, the Company has estimated a fair value of $0 related to the Gateway contingent consideration as the achievement of the contingent consideration targets is not considered probable.